Hostname: page-component-89b8bd64d-nlwjb Total loading time: 0 Render date: 2026-05-08T13:03:12.681Z Has data issue: false hasContentIssue false

Preeclampsia and risk of maternal pulmonary hypertension at high altitude in Bolivia

Published online by Cambridge University Press:  27 July 2023

C. E. Salinas
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
O. V. Patey
Affiliation:
Department of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK
C. Murillo
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
M. Gonzales
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
V. Espinoza
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
S. Mendoza
Affiliation:
Centro de Salud Tembladerani, La Paz, Bolivia
R. Ruiz
Affiliation:
Hospital Materno Infantil, La Paz, Bolivia
R. Vargas
Affiliation:
Hospital de la Mujer, La Paz, Bolivia
Y. Perez
Affiliation:
Hospital de la Mujer, La Paz, Bolivia
J. Montaño
Affiliation:
Hospital de la Mujer, La Paz, Bolivia
L. Toledo-Jaldin
Affiliation:
Hospital Materno Infantil, La Paz, Bolivia
A. Badner
Affiliation:
Hospital Materno Infantil, La Paz, Bolivia
J. Jimenez
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
J. Peñaranda
Affiliation:
Facultad de Medicina, UMSA, La Paz, Bolivia
C. Romero
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
M. Aguilar
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
L. Riveros
Affiliation:
Instituto Boliviano de Biología de Altura (IBBA), UMSA, La Paz, Bolivia
I. Arana
Affiliation:
Grupo Premio Nobel, La Paz, Bolivia
D. A. Giussani*
Affiliation:
Department of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK BHF Centre for Research Excellence, University of Cambridge, Cambridge, UK Strategic Research Initiative in Reproduction, University of Cambridge, Cambridge, UK
*
Corresponding author: Dino A. Giussani; Email: dag26@cam.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Women with a history of preeclampsia (PE) have a greater risk of pulmonary arterial hypertension (PAH). In turn, pregnancy at high altitude is a risk factor for PE. However, whether women who develop PE during highland pregnancy are at risk of PAH before and after birth has not been investigated. We tested the hypothesis that during highland pregnancy, women who develop PE are at greater risk of PAH compared to women undergoing healthy highland pregnancies. The study was on 140 women in La Paz, Bolivia (3640m). Women undergoing healthy highland pregnancy were controls (C, n = 70; 29 ± 3.3 years old, mean±SD). Women diagnosed with PE were the experimental group (PE, n = 70, 31 ± 2 years old). Conventional (B- and M-mode, PW Doppler) and modern (pulsed wave tissue Doppler imaging) ultrasound were applied for cardiovascular íííassessment. Spirometry determined maternal lung function. Assessments occurred at 35 ± 4 weeks of pregnancy and 6 ± 0.3 weeks after birth. Relative to highland controls, highland PE women had enlarged right ventricular (RV) and right atrial chamber sizes, greater pulmonary artery dimensions and increased estimated RV contractility, pulmonary artery pressure and pulmonary vascular resistance. Highland PE women had lower values for peripheral oxygen saturation, forced expiratory flow and the bronchial permeability index. Differences remained 6 weeks after birth. Therefore, women who develop PE at high altitude are at greater risk of PAH before and long after birth. Hence, women with a history of PE at high altitude have an increased cardiovascular risk that transcends the systemic circulation to include the pulmonary vascular bed.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press in association with International Society for Developmental Origins of Health and Disease
Figure 0

Table 1. Maternal data of controls vs preeclamptic women before and after birth

Figure 1

Figure 1. Maternal right heart geometry for controls and preeclamptic women. Column plots demonstrate significant perinatal alterations in right heart geometrical parameters in preeclamptic women [PE] (in blue) compared to healthy controls [C] (in pink): A. Right ventricular (RV) end-diastolic dimension (EDD) derived in the parasternal long axis view (PLAX); B. RV end-systolic dimension (ESD) obtained in PLAX; C. RV EDD obtained in the four-chamber view (4CHV); D. RV end-diastolic length (EDL) derived in 4CHV; E. RV relative wall thickness (RWT); F. Right atrial (RA) ESD; G. RA end-systolic area (ESA); H. Main pulmonary artery (MPA) dimension. Values are means ± SEM. The effect of preeclampsia was determined by two-way ANOVA. Significant differences between groups: ****, p < 0.0001; ***, p < 0.001; **, p < 0.01. RWT = (RV free wall thickness)2/RV EDD. Abbreviations: EDD, end-diastolic dimension; EDL, end-diastolic length; ESA, end-systolic area; ESD, end-systolic dimension; MPA, main pulmonary artery; PLAX, parasternal long axis; RA, right atrium; RV, right ventricle; RWT, relative wall thickness; 4CHV, four-chamber view.

Figure 2

Figure 2. Maternal right heart function and indices of pulmonary hypertension for controls and preeclamptic women. Column plots demonstrate significant perinatal alterations in right ventricular functional indices in preeclamptic women [PE] (in blue) compared to healthy controls [C] (in pink): A. Tricuspid annular plane systolic excursion (TAPSE); B. Tricuspid regurgitation peak systolic velocity (TR Vmax); C. Right atrium to right ventricle peak gradient (RA-rV PG); D. Pulmonary valve velocity time integral (PV VTI); E. Mean pulmonary artery pressure (PAP); F. Pulmonary vascular resistance (PVR). Values are means ± SEM. The effect of preeclampsia was determined by two-way ANOVA. Significant differences between groups: ****, p < 0.0001; ***, p < 0.001; **, p < 0.01. abbreviations: PAP, pulmonary artery pressure; PG, peak gradient; PVR, pulmonary vascular resistance; PV, pulmonary valve; RA, right atrium; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; Vmax, maximal velocity; VTI, velocity time integral.

Figure 3

Figure 3. Maternal respiratory health for controls and preeclamptic women. Column plots demonstrate significant perinatal alterations in respiratory indices in preeclamptic women [PE] (in blue) compared to healthy controls [C] (in pink): A. Oxygen saturation (O2 sat); refers to peripheral O2 saturation; B. Forced vital capacity (FVC); C. Forced expiratory volume in 1 s (FEV1); D. FEV1 to FVC ratio (FEV1/FVC); E. Forced expiratory flow at 50% of vital capacity (FEF50%); F. Forced expiratory flow at 75% of vital capacity (FEF75%). Values are means ± SEM. The effect of preeclampsia was determined by two-way ANOVA. Significant differences between groups: ****, p < 0.0001; ***, p < 0.001; **, p < 0.01. Abbreviations: FEF, forced expiratory flow; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; L, litre; O2 sat, peripheral oxygen saturation.